Chris Williamson - Iradimed Executive Technology
| IRMD Stock | USD 43.85 1.85 4.40% |
Executive
Chris Williamson is Executive Technology of Iradimed Co
| Address | 1025 Willa Springs Drive, Winter Springs, FL, United States, 32708 |
| Phone | 407 677 8022 |
| Web | https://www.iradimed.com |
Iradimed Management Efficiency
The company has return on total asset (ROA) of 0.141 % which means that it generated a profit of $0.141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.237 %, meaning that it created $0.237 on every $100 dollars invested by stockholders. Iradimed's management efficiency ratios could be used to measure how well Iradimed manages its routine affairs as well as how well it operates its assets and liabilities. As of May 3, 2024, Return On Tangible Assets is expected to decline to 0.17. In addition to that, Return On Capital Employed is expected to decline to 0.24. At present, Iradimed's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.3 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bradley Nagel | Electromed | 42 | |
| Michael Finegan | Orthofix Medical | 53 | |
| Chris Calcaterra | Glaukos Corp | 64 | |
| Mehul Joshi | PulmonxCorp | 63 | |
| Matthew III | LivaNova PLC | N/A | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Stephen Mascioli | Anika Therapeutics | 61 | |
| Julie Andrews | Orthofix Medical | 53 | |
| Bryan Olin | LivaNova PLC | 57 | |
| Christopher Lewis | Glaukos Corp | N/A | |
| William George | Electromed | 75 | |
| Teryl Sides | SurModics | 54 | |
| Edward Ahn | Anika Therapeutics | 44 | |
| Michele Allegretto | Glaukos Corp | N/A | |
| Ben Joseph | Anika Therapeutics | N/A | |
| Deanna Wilke | LivaNova PLC | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Brent Lalomia | CONMED | 49 | |
| Douglas Manko | LivaNova PLC | 44 | |
| Lisa Funiciello | Anika Therapeutics | N/A | |
| Stephen JD | Sight Sciences | N/A | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.14 |
Iradimed Leadership Team
Elected by the shareholders, the Iradimed's board of directors comprises two types of representatives: Iradimed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iradimed. The board's role is to monitor Iradimed's management team and ensure that shareholders' interests are well served. Iradimed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iradimed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francis Casey, Vice President - Regulatory and Quality Assurance | ||
| Randy Waddell, Vice Marketing | ||
| Lynn Neuhardt, Vice Development | ||
| Fran Casey, VP of Regulatory and Quality Assurance | ||
| Serge Novovich, Independent Director | ||
| Chris Williamson, Executive Technology | ||
| Matt Garner, Controller | ||
| Steve Kachelmeyer, Vice Assurance | ||
| Louis Waldman, Controller | ||
| Jonathan Kennedy, Director | ||
| John Glenn, Chief Officer | ||
| Roger Susi, Founder, CEO and President and Director | ||
| Steve Nardi, VP of Manufacturing | ||
| James Hawkins, Independent Chairman of the Board | ||
| John McCreery, COO | ||
| Anthony Vuoto, Director | ||
| Brent Johnson, Executive VP of Worldwide Sales and Marketing | ||
| Chris Scott, CFO, Secretary | ||
| Monty Allen, Independent Director |
Iradimed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iradimed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 484.12 M | ||||
| Shares Outstanding | 12.64 M | ||||
| Shares Owned By Insiders | 37.03 % | ||||
| Shares Owned By Institutions | 55.05 % | ||||
| Number Of Shares Shorted | 104.88 K | ||||
| Price To Earning | 28.70 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iradimed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iradimed's short interest history, or implied volatility extrapolated from Iradimed options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.231 | Dividend Share 0.15 | Earnings Share 1.35 | Revenue Per Share 5.202 | Quarterly Revenue Growth 0.174 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.